ArticleHepatology international2023

Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.

Jin Lei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.